Cargando…

Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is closely associated with inflammation and chronic infection. Antibiotics are frequently prescribed for NSCLC patients in combination with epidermal growth factor receptor (EGFR)-targeted treatment in the presence of infection. The association between antibiotic u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Kejun, Zhang, Weiwei, Tan, Qinquan, Jiang, Guanming, Jia, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676747/ https://www.ncbi.nlm.nih.gov/pubmed/31404289 http://dx.doi.org/10.3892/ol.2019.10481

Ejemplares similares

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis
por: Yang, Xiaojun, et al.
Publicado: (2022)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities
por: Dsouza, Philomena Charlotte, et al.
Publicado: (2017)

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
por: Jiang, Shirley Xue, et al.
Publicado: (2019)

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Toxic Epidermal Necrolysis
por: Khalifian, Saami, et al.
Publicado: (2014)

Toxic epidermal necrolysis
por: Hoetzenecker, Wolfram, et al.
Publicado: (2016)

Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
por: Zhang, Minghui, et al.
Publicado: (2016)

Epidermal growth factor receptors in non-small cell lung cancer.
por: Veale, D., et al.
Publicado: (1987)

Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis
por: Kian, Waleed, et al.
Publicado: (2021)

Multiple drugs: Toxic epidermal necrolysis and lack of efficacy: case report
Publicado: (2022)

Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma
por: Sharma, Saniya, et al.
Publicado: (2018)

The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients
por: Liu, Lanlan, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review
por: Launay, Simon G, et al.
Publicado: (2011)

Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer
por: He, Wenjie, et al.
Publicado: (2016)

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
por: Alanazi, Abdullah, et al.
Publicado: (2020)

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer
por: Tinsley, N., et al.
Publicado: (2022)

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
por: Chen, Minjiang, et al.
Publicado: (2019)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

Impact of Antibiotics Associated with the Development of Toxic Epidermal Necrolysis on Early and Late-Onset Infectious Complications
por: Lipovy, Bretislav, et al.
Publicado: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas
por: Changavi, Arathi A, et al.
Publicado: (2015)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
por: Qin, Haifeng, et al.
Publicado: (2021)

Review of Toxic Epidermal Necrolysis
por: Harris, Victoria, et al.
Publicado: (2016)

Toxic Epidermal Necrolysis and Sepsis
por: Alves, Daniela Dias, et al.
Publicado: (2016)

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
por: Xu, Hongyu, et al.
Publicado: (2020)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020)

Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis
por: Hasegawa, Akito, et al.
Publicado: (2020)

Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer
por: Dang, Yutao, et al.
Publicado: (2020)

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
por: Li, Gang, et al.
Publicado: (2022)

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients
por: Rodriguez, Pedro C, et al.
Publicado: (2011)

Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
por: Zhao, Yi, et al.
Publicado: (2019)

Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors
por: POPA, CRISTINA-MARIA, et al.
Publicado: (2021)

Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases
por: Lu, Angela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qebmlnhnu63ug6b8ctf4qhuuer